Table 1.
Baseline characteristics
| Characteristic | N = 73 |
|---|---|
| Age, year | 49 (18–74) |
| Female | 57 (78) |
| PAH etiology | |
| Idiopathic or hereditary | 35 (48) |
| Collagen vascular disease | 16 (22) |
| Othera | 22 (30) |
| Background PAH therapy | |
| ERA only | 19 (26) |
| PDE-5 inhibitor only | 8 (11) |
| Both | 43 (59) |
| None | 3 (4) |
| WHO functional class | |
| I | 1 (1) |
| II | 41 (56) |
| III | 31 (42) |
| IV | 0 (0) |
| 6MWD, m | 378 (330–452) |
| NT-proBNP, pg/mL | 626 (222–1330) |
Values are mean (range) for age and median (interquartile range) for 6MWD and NT-proBNP. All other values are n (%). PAH, pulmonary arterial hypertension; ERA, endothelin receptor antagonist; PDE-5, phosphodiesterase type 5; WHO, World Health Organization; 6MWD, 6-min walk distance; NT-proBNP, N-terminal pro-B-type natriuretic peptide.
a
Other PAH Etiology includes HIV infection (n = 3), repaired congenital shunt (n = 4), and unrepaired congenital shunt (n = 15).